IRCT20201221049782N1已完成3 期
Clinical efficacy and safety of loratadine in treating irritable bowel syndrome with predominant diarrhea
Pharmachemie pharmaceutical factory0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Patients with IBS-D
- •Age between 18 and 65
- •No abnormalities on physical examination
- •Routine CBC
- •No abnormalities observed by Sigmoidoscopy
- •Normal thyroid function
- •Negative routine stool examinations
排除标准
- •Renal impairment
- •Cardiovascular disorders
- •Psychiatric disorders
- •Celiac disease
- •Use of drugs that affect the digestive system
- •Use of Analgesics
- •Use of Antihistamines
- •Loratadine intolerance
研究者
相似试验
尚未招募
Unknown
Real world study of lorlatinib in previously untreated ALK positive lung cancerCTRI/2024/03/063721Pfizer Products India Private Limited
已完成
不适用
Evaluation of the clinical usefulness of rupatadine in patients with seasonal allergic rhinitisSeasonal allergic rhinitisJPRN-UMIN000031360Medical Corporation Shinanokai, Shinanozaka Clinic100
已完成
3 期
Effect of Thalidomide in Covid 19 pneumoniaPneumonia caused by Coronavirus 2019, COVID19.Coronavirus infection, unspecifiedB34.2IRCT20200428047232N1Esfahan University of Medical Sciences60
已完成
不适用
oratadine effect on the rate of rehospitalization and recurrent angina in patients with acute coronary syndromeacute coronary syndrome.Acute ischaemic heart disease, unspecifiedIRCT138903131061N7Rafsanjan University of Medical Sciences200
已完成
不适用
The efficacy and safety of Tadarafil for treatment of nocturia and sleep qualityJPRN-UMIN000018292Fujita Health University50